What is TRDA's current stock price?

TRDA (Entrada Therapeutics, Inc.) is currently trading at $6.56 with a market cap of $254.7M.

What sector is Entrada Therapeutics, Inc. in?

Entrada Therapeutics, Inc. (TRDA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TRDA a good stock to buy?

Analysts have a Buy consensus on TRDA with a price target of $17.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TRDA Entrada Therapeutics, Inc.

Healthcare

$6.56+3.96%ClosedMarket Cap: $254.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.01

P/S

44.38

EV/EBITDA

-1.33

DCF Value

$9.48

FCF Yield

-51.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

-598.0%

Operating Margin

-3109.3%

Net Margin

-2895.1%

ROE

-51.2%

ROA

-49.5%

ROIC

-55.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$875.0K	$-39.7M	$—
Q4 null	$1.3M	$-39.2M	$—
FY null	$25.4M	$-143.8M	$—
Q3 null	$1.6M	$-44.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.00

Target (Median)

$20.00

Target Range

$10.00 - $21.00

0 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Neutral

2026-05-08

OppenheimerOutperform

2026-04-06

HC Wainwright & Co.Buy

2026-02-18

Trading Activity

Insider Trades

View All

Zeiher Bernhardt Gdirector

BuyThu May 21

Sethuraman Natarajanofficer: President, Research & Develop.

SellMon May 04

Dowden Nathan Jofficer: President & COO

SellMon May 04

Dowden Nathan Jofficer: President & COO

SellMon May 04

WENTWORTH KORY JAMESofficer: Chief Financial Officer

SellThu Apr 02

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.09

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Peers